EA201992885A1 - Антитела, специфически связывающиеся с pd-1, и способы их применения - Google Patents

Антитела, специфически связывающиеся с pd-1, и способы их применения

Info

Publication number
EA201992885A1
EA201992885A1 EA201992885A EA201992885A EA201992885A1 EA 201992885 A1 EA201992885 A1 EA 201992885A1 EA 201992885 A EA201992885 A EA 201992885A EA 201992885 A EA201992885 A EA 201992885A EA 201992885 A1 EA201992885 A1 EA 201992885A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ways
application
specifically binding
antibodies specifically
antibodies
Prior art date
Application number
EA201992885A
Other languages
English (en)
Inventor
Цян ЧЭНЬ
Сьюзанн Коул
Карен Даффи
Дебра Гарднер
Янься Го
Деймон Хэмел
Шэннон Хитчкок
Энн Лакомб
Цзиньцюань Ло
Рави Малавия
Евгения Орловски
Педжман Соруш
Мелисса Свиецки
Дипти Уилкинсон
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Priority claimed from PCT/US2018/035843 external-priority patent/WO2018226580A2/en
Publication of EA201992885A1 publication Critical patent/EA201992885A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Антитела, которые специфически связываются с PD-1, или их антигенсвязывающие фрагменты, полинуклеотиды, кодирующие антитела или фрагменты, а также способы получения и применения вышеуказанного можно использовать для лечения воспалительных или иммунных расстройств.
EA201992885A 2018-05-18 2018-06-04 Антитела, специфически связывающиеся с pd-1, и способы их применения EA201992885A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862673185P 2018-05-18 2018-05-18
PCT/US2018/035843 WO2018226580A2 (en) 2017-06-05 2018-06-04 Antibodies that specifically bind pd-1 and methods of use

Publications (1)

Publication Number Publication Date
EA201992885A1 true EA201992885A1 (ru) 2020-05-15

Family

ID=70847679

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992885A EA201992885A1 (ru) 2018-05-18 2018-06-04 Антитела, специфически связывающиеся с pd-1, и способы их применения

Country Status (1)

Country Link
EA (1) EA201992885A1 (ru)

Similar Documents

Publication Publication Date Title
EA202092847A1 (ru) Антитела к cd3 и их применение
MX2019014577A (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso.
SA522431756B1 (ar) Tigit أجسام مضادة لـ
EA202092839A1 (ru) Агенты, связывающиеся с psma, и виды их применения
EA201990243A1 (ru) Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения
EA201891093A1 (ru) Антитела, специфически связывающие pd-1, и их применение
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201990594A1 (ru) Анти-tim-3 антитела и их применение
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA202192736A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с псма
EA201890834A1 (ru) Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
MX390920B (es) Moléculas de unión a lag-3 y métodos de uso de las mismas.
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201890143A2 (ru) Антитела против pdgfr-бета и их применения
MX382398B (es) Proteinas de union a antigeno st2.
EA201290589A1 (ru) Cd127-связывающие белки
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение